![]()
|
|
||||||||
J. Biol. Chem., Vol. 275, Issue 30, 22611-22614, July 28, 2000
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,
,
,
From the Center for Molecular and Vascular Biology and
Laboratory of Physiology, University of Leuven, B-3000
Leuven, Belgium
Received for publication, May 5, 2000, and in revised form, May 15, 2000
| |
ABSTRACT |
|---|
|
|
|---|
The P2X1 receptor belongs to a family of
oligomeric ATP-gated ion channels with intracellular N and C termini
and two transmembrane segments separating a large extracellular domain.
Here, we describe a naturally occurring dominant negative P2X1 mutant.
This mutant lacks one leucine within a stretch of four leucine residues
in its second transmembrane domain (TM2) (amino acids 351-354).
Confocal microscopy revealed proper plasma membrane localization of the mutant in stably transfected HEK293 cells. Nevertheless,
voltage-clamped HEK293 cells expressing mutated P2X1 channels failed to
develop an ATP or ADP-induced current. Furthermore, when co-expressed with the wild type receptor in Xenopus oocytes, the mutated
protein exhibited a dose-dependent dominant negative effect
on the normal ATP or ADP-induced P2X1 channel activity. These data
indicate that deletion of a single apolar amino acid residue at the
inner border of the P2X1 TM2 generates a nonfunctional channel. The inactive and dominant negative form of the P2X1 receptor may constitute a new tool for the study of the physiological role of this channel in
native cells.
The P2X receptors are oligomeric nonselective ATP-gated cation
channels that are expressed in many excitable and nonexcitable cells
where they mediate a variety of physiological actions, including central and peripheral neurotransmission, smooth muscle contraction, and hormone secretion (1, 2). Seven P2X receptors have been identified
at the molecular level (3). The P2X1 receptor subtype is found
primarily on visceral and vascular smooth muscle cells (4), but is also
present in large quantities on platelets (5). In these tissues, the
P2X1 receptors account for the rapidly inactivating Several mutagenesis analyses have been performed to identify P2X
receptor subdomains involved in hetero- and homo-oligomeric subunit
assembly (9), and in the control of receptor desensitization (10-12),
or to identify amino acid residues contributing to the pore of P2X
channels (13, 14). Still little is known about P2X receptor primary or
secondary structures participating in membrane sidedness, subunit
stoichiometry, ligand binding site, and gating properties of the channels.
We have identified a mutation in the platelet P2X1 receptor of a
patient showing a severe bleeding disorder. This mutation corresponds
to the loss of one leucine residue located between leucine residues
351-353 at the inner border of the second transmembrane domain of the
channel. The single amino acid residue deletion resulted in the
expression of nonfunctional channels in HEK293 cells. Furthermore, the
mutated receptor acted as a dominant negative molecule when
co-expressed with the wild type receptor in Xenopus oocytes.
Patient Description--
The propositus is a 6-year-old girl,
second child of two healthy unrelated parents; her sister is healthy.
She was referred to our hospital at the age of 19 months because of
pronounced bleeding: after a fulminant nose bleed, she was hospitalized
in the intensive care unit for severe exsanguination (hemoglobin drop
from 121 to 60 g/liter). Local examination of the nasal mucosa revealed
diffuse oozing, without local vascular dilatation. Recurrent bleeding
was evidenced by low plasma iron levels and increased reticulocyte
numbers. Further spontaneous mucosal nose bleeding could be stopped
only by administration of tranexamic acid and platelet transfusions.
Moreover, she continuously has spontaneous generalized petechiae and
ecchymoses. Coagulation parameters, von Willebrand factor antigen, and
function were completely normal. Platelet count and size were normal as
well as platelet morphology, studied by electron microscopy. Platelet
aggregation in response to the 14-mer TRAP peptide, arachidonic acid,
and ristocetin was unaltered. The patient showed, however, a selective
impairment of the ADP-induced platelet aggregations.
Natural Mutation in the P2X1 Receptor cDNA and Expression
Vectors--
Full-length patient platelet P2X1 cDNAs were obtained
by reverse transcriptase-polymerase chain reaction using primers
encompassing the coding region of the cDNA: P2X1,
5'-CCCACCATGGCACGGCGGTTCCAGGAGG-3' (sense),
5'-TCAGGATGTCCTCATGTTCTCCTGCAGG-3' (antisense). The polymerase chain reaction fragments were cloned into the PCR2.1-TOPO vector (TOPO
TA cloning kit, InVitrogen). Individual clones were sequenced using the
AutoRead Sequencing kit (Amersham Pharmacia Biotech) on the automated
A.L.F. sequencer (Amersham Pharmacia Biotech). PCR2.1-TOPO vector
clones containing either wild type (P2X1WT) or mutated (P2X1delL)
cDNAs were digested with EcoRI restriction enzyme, and
the purified fragments were subcloned into the
EcoRI-digested pcDNA3.1 (InVitrogen) or bicistronic
pCINeoIRES-GFP1 (15)
expression vectors. The resulting expression vectors were used for T7
promoter driven in vitro transcription (RiboMax Large Scale
RNA Production System, Promega) for injection into Xenopus oocytes or transfection of HEK293 cells (FuGene 6 reagent, Roche Molecular Biochemicals).
Cell Culture and Xenopus Oocyte Isolation and
Microinjection--
HEK293 cells were maintained in Dulbecco's
modified Eagle's medium cell culture medium supplemented with 2%
penicillin-streptomycin, 2% L-glutamine, 1% nonessential
amino acids and 10% fetal bovine serum (Life Technologies, Inc.).
Stable transfectants were obtained via selection with G418 (800 µg/ml). Ovarian lobes were removed from mature female Xenopus
laevis, treated with 2 mg/ml collagenase A (Roche Molecular
Biochemicals) for 1.5-2 h, and stage V and VI oocytes were selected.
After cytoplasmic microinjections, the oocytes were incubated for
48-72 h at 18 °C in ND 96 solution (96 mM NaCl, 2 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, 5 mM Hepes, pH 7.5, 100 units/ml penicillin-streptomycin, 2.5 mM sodium pyruvate).
Preparation of P2X1-specific Antiserum and Western
Blotting--
A rabbit antiserum specific to the extracellular domain
of human P2X1 was obtained by injection of a homemade glutathione S-transferase protein fused to amino acid residues 61-318
of the P2X1 receptor using standard methods. Cytosolic and membrane
fractions of HEK293 cell extracts were analyzed in Western blotting
using this antiserum. Protein concentrations in the extracts were
determined using the Bradford assay.
Immunostaining and Confocal Microscopy--
Stably transfected
HEK293 cells were plated on polylysine-coated (0.1 mg/ml, Sigma)
culture slides at 5 × 105 cells/ml density. Fixed
(methanol) and permeabilized (1% Triton X-100) cells were incubated
with the polyclonal rabbit P2X1 antiserum, before detection with goat
anti-rabbit-fluorescein isothiocyanate (Dako A/S, Glostrup, Denmark).
Immunofluorescence was visualized in a Zeiss LSM510 confocal microscope
(× 40 magnification).
Electrophysiological Recordings--
Transfected HEK293 cells
were analyzed 36-72 h after transfection using the whole cell patch
clamp method. The standard external bath solution contained 150 mM NaCl, 6 mM CsCl, 1 mM
MgCl2, 1.5 mM CaCl2, 10 mM Hepes, 10 mM glucose, 50 mM
mannitol, pH 7.4. The pipette solution contained: 40 mM
CsCl, 100 mM aspartic acid, 1 mM
MgCl2, 10 mM Hepes, 5 mM EGTA,
1.928 mM CaCl2, pH 7.2. Pipette resistance was
between 7.5 and 2.5 megohms. Whole cell currents in the ruptured
membrane mode were continuously recorded for 10 s at Normal Membrane Localization of P2X1delL Channels--
The
mutation described is an in-frame deletion of three nucleotides in the
sequence CTGCTGCTG located between positions 1051 and 1059 of the patient platelet P2X1 cDNAs (Fig.
1, A and B). Both
normal and mutated P2X1 cDNAs were identified in the patient's platelets. Neither P2X1 cDNAs from the patient reticulocytes nor the P2X1 gene from the patient neutrophil and mononuclear cells contained the mutation, which is thus likely of clonal origin. The P2X
ionotropic receptors have two putative transmembrane domains (TM1 and
TM2) separated by a large extracellular region, with both the N and C
termini located inside the cell (3). The mutation results in deletion
of one of the Leu-351, Leu-352, or Leu-353 residues within a stretch of
four leucine residues contained in the TM2 domain of the P2X1 receptor
(amino acids 351-354) (Fig. 1C). To compare the subcellular
localization as well as the expression levels of wild type (P2X1WT) and
mutated (P2X1delL) P2X1 receptors in transfected HEK293 cells, we
produced a polyclonal antibody directed against the extracellular
domain of the protein that recognized both receptors.
Immunofluorescence and confocal microscopy revealed normal membrane
localization of the P2X1delL receptors in stably transfected cells
(Fig. 2A), indicating that the
mutation does not affect the sorting and/or the processing of the
protein. Western blotting experiments on membrane and cytosolic cell
fractions confirmed membrane localization of the mutated receptor and
showed similar expression levels for P2X1WT and P2X1delL (Fig.
2B). No P2X1 protein was detected in nontransfected HEK293
cells (Fig. 2, A and B).
Heterologous Expression of P2X1delL Receptor Creates Nonfunctional
Channels--
Functional comparison of P2X1delL and P2X1WT was
performed in voltage-clamped HEK293 cells transiently transfected with
a bicistronic expression vector encoding P2X1delL or P2X1WT together with the GFP. As described previously (16), P2X1WT generated a robust,
quickly desensitized, inward current during conventional whole cell
patch clamp measurements. This typical P2X1 phenotype current was
recorded from all P2X1WT-transfected green cells. The current density
in response to 100 µM ATP was 398.7 pA/pF1
(S.E. = 91.8 pA/pF, n = 9) (Fig.
3A) at a holding potential of Dominant Negative Effect of P2X1delL on Normal P2X1
Activity--
Since the P2X receptors have been shown to form stable
homo- or hetero-oligomers in cell membranes (3), we wondered whether the inactive P2X1delL receptor could disturb P2X1WT activity in a
co-expression system. For this purpose, Xenopus oocytes were co-injected with both receptor cRNAs. Oocytes expressing P2X1WT receptors alone (10 ng of cRNA) showed robust ATP-induced whole cell
currents with amplitudes in the range of 1.3-2.4 µA at negative holding potential (mean peak value taken as 100%) (Fig.
4A), whereas oocytes
expressing P2X1delL (10 ng of cRNA) failed to develop any significant
current, confirming the results observed in HEK293 cells. In
co-expression experiments, maintaining a total amount of injected cRNAs
of 10 ng, 5 ng of P2X1WT combined with 5 ng of P2X1delL cRNAs resulted
in a stronger reduction of the peak current amplitude (to 15%) than
expected from injection of 5 ng of active P2X1WT cRNAs alone. These
data indicated a dominant negative effect of the mutated receptor on
the normal P2X1 channel activity. This effect was investigated
dose-dependently by co-injecting 10 ng P2X1WT with 10 or 5 ng P2X1delL cRNAs. Co-injection of 10 ng of P2X1WT with 10 ng of
P2X1delL cRNAs resulted in the development of a current reduced by 50%
compared with the P2X1WT (10 ng) reference current, whereas
co-injection of 10 ng of P2X1WT cRNA with 5 ng of P2X1delL led to 30%
reduction, showing dose dependence of the dominant negative effect.
The mutation presently described is an in-frame deletion of three
nucleotides, which results in the loss of one leucine residue (Leu-351,
Leu-352, or Leu-353) within a stretch of four leucine residues located
between amino acids 351 and 354 of the P2X1 receptor. Heterologous
expression of the P2X1WT receptor results in quickly desensitized ATP-
or ADP-induced cation-selective inward rectifying currents.
Interestingly, P2X1delL-expressing HEK293 cells or Xenopus oocytes failed to develop an ADP- or ATP-induced current. This lack of
function was not due to improper targeting and insertion of the channel
into the plasma membrane as evidenced by confocal microscopy following
immunostaining. The leucine deletion is located in a domain (TM2
spanning residues 332-357) of P2X1, which is thought to traverse the
lipid membrane, forming part of the ion-conducting region of every
P2X-type receptor (3). Positioning of the P2X receptor subunit in the
membrane has been assigned from a range of experiments analyzing the
effect of extracellular application of methanethiosulfonates on the
currents evoked by ATP following substitution of residues 316-354 of
P2X2 by cysteine (13, 14). The D349C substitution was unique as only
the smaller ethylamine derivative ((2-aminoethyl)methanethiosulfonate)
inhibited the current after channel opening with ATP, indicating that
Asp-349 is located on the intracellular side of the channel gate. This aspartate residue, corresponding to Asp-350 of P2X1, and conserved in
all P2X receptors, precedes the leucine deletion identified in P2X1
(Leu-351 to Leu-353) (Fig. 5). The
deletion is thus localized in the inner proximal neighborhood of the
intracellular channel gate (Fig. 5). It is also contained in a stretch
of three apolar residues with conserved hydrophobicity among all P2X
receptors. As no P2X2 functional loss was observed when these residues
were substituted in cysteine (13, 14), our findings imply that the
deletion results in the disruption of an important channel structure
comprising the highly conserved apolar residue stretch. Thus, our data
point to the involvement of these residues in critical structural
attributes of the P2X1 channel and potentially of the other P2X-type
channels.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
,
methylene
ATP-sensitive native P2X receptor phenotype (4, 6). However, because of
the lack of potent and selective P2X receptor antagonists, the
physiological role of P2X1 receptors has been difficult to unravel.
Recently, the generation of P2X1 receptor-deficient mice demonstrated
that P2X1 receptors are essential for normal male reproductive function
via their role in vas deferens contraction in response to sympathetic
nerve stimulation (7). However, its role in platelet function remains
unclear (8).
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
80 mV
holding potential. To determine IV relationship, we applied short (500 ms) RAMP (from
100 to +100 mV) before and during agonist application.
The agonists were applied using a fast application system. Current
measurements on Xenopus oocytes were performed by a
two-electrode voltage clamp technique. Oocytes were maintained in a
continuously perfused (3 ml/min) small volume (250 µl) chamber. 100 µM niflumic acid was added in the external ND 96 solution
to prevent activation of endogenous
Ca2+-dependent chloride channels. The currents
were recorded at
60 mV holding potential. The P2X1 channel-generated
inward current was activated by applying 250 µl of 100 µM ATP solution from a pipette above the oocyte. Data
were analyzed with WinASCD 5.0 software (G. Droogmans, Leuven,
Belgium). Statistical comparison was made using the nonpaired
Student's t test.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (40K):
[in a new window]
Fig. 1.
Mutation in the patient platelet P2X1
cDNAs. A, the sequence displays the nucleotides
1026-1069 of the normal P2X1 cDNA (GenBankTM accession
number AF020498). B, mutated fragment containing an in-frame
three nucleotide deletion. The position of the translated leucine
residues is indicated. C, schematic representation of the
mutated P2X1 protein structure and the site of the mutation
(crossed open symbol).

View larger version (16K):
[in a new window]
Fig. 2.
Normal membrane localization and expression
levels of P2X1delL. A, confocal microscopy.
Immunostaining of the P2X1WT (WT) and P2X1delL
(delL) in stably transfected HEK293 cells. Nontransfected
cells (NT) are shown as negative controls. B,
Western blots performed on P2X1WT and P2X1delL-expressing HEK293 cell
extracts (c, cytosol; m, membrane fraction).
Nontransfected (NT) cell membrane extracts are also
shown.
80 mV. Fig. 3B represents instantaneous I-V relationship
before and after ATP application, clearly showing the reversal of the ATP-induced current at +5 mV, which is characteristic for P2X1-mediated cation current (17). ADP (50 µM) application induced a
current of 333.6 pA/pF (S.E. = 20.7 pA/pF, n = 9) with
a slower channel desensitization time course (Fig. 3C).
Interestingly, in P2X1delL-transfected cells, agonist application (50 µM ADP) failed to evoke membrane currents at identical
holding potential (n = 5) (Fig. 3E), and 100 µM ATP could induce an extremely small inward current in
66% of the transfected cells (current density was 6.89 pA/pF, S.E. = 2.34 pA/pF, mean peak current = 87 pA, n = 6)
(Fig. 3D). The nontransfected HEK293 cells or those cells,
which did not emit green fluorescence, did not respond to agonist
application (data not shown, n = 5).

View larger version (13K):
[in a new window]
Fig. 3.
P2X1WT and P2X1delL channel activity in
transfected HEK293 cells. ATP- (100 µM)
(A) and ADP- (50 µM) (C) induced
inward currents in P2X1WT-expressing cells. Corresponding I-V curves
recorded in the presence (ATP) or absence
(Control) of 100 µM ATP (B). Whole
cell currents in P2X1delL-expressing HEK293 cells in response to 100 µM ATP (D) or 50 µM ADP
(E). Agonist application is depicted by arrows,
application lasted for 5 s.
= level of zero current.

View larger version (24K):
[in a new window]
Fig. 4.
Co-expression of P2X1WT and P2X1delL
receptors in Xenopus oocytes. A,
currents evoked by 100 µM ATP in P2X1WT- and
P2X1delL-expressing oocytes after cytoplasmic microinjection of the
indicated amount of cRNA. Mean peak values (±S.E.) were normalized to
oocytes injected with 10 ng P2X1WT cRNA (100%) and expressed in
percentage. B, corresponding representative inward current
profiles. The left bar corresponds to the zero current
level. The arrows represent the time point of agonist
application (*, p < 0.05; **, p < 0.005 versus the wild type 10 ng reference).
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (20K):
[in a new window]
Fig. 5.
Sequence alignment of the TM2 of all P2X
receptors. Conserved amino acid residues are boxed with
solid lines; the three-apolar residue stretch is
boxed with a dashed line. The position of the
deletion affecting residues Leu-351, Leu-352, or Leu-353 of P2X1 is
depicted with circles.
P2X receptor subunits assemble into homo- and hetero-oligomeric channels (3). Co-expression experiments performed in Xenopus oocytes indicated that the mutant receptor has a dose-dependent dominant negative effect on the normal P2X1 channel activity. Indeed, the channel phenotype observed after co-injection of different ratios between the P2X1WT and P2X1delL subunits leads to a weaker current than expected from addition of individual subunit phenotypes, indicating that the mutated subunit dominates the phenotype of the resulting channel. This dominant negative effect may rely on the fact that P2X1delL subunits are still able to assemble with the P2X1WT subunits, forming nonfunctional hetero-oligomers in oocyte membranes. The chimera study of Torres et al. (9) showed that TM2 is a critical determinant of P2X subunit assembly; it seems, however, that amino acid residues distinct from Leu-351 to Leu-353 of the P2X1 subunit are responsible for the assembly. Current studies aim at determining whether the presence of this single leucine deletion in P2X1WT/P2X1delL hetero-oligomers affects either the single channel conductance or the probability of channel opening.
In co-immunoprecipitation assays, P2X1 subunits were shown to assemble with most of the other P2X subunits (P2X2, P2X3, P2X5, and P2X6) (18), resulting in a channel with a novel phenotype in the case of P2X5 (19). It would be interesting to determine whether the P2X1delL subunit can still assemble with these P2X subunits and abolish the channel activity. If so, the P2X1 dominant negative mutant would constitute a novel selective tool that should facilitate the study of the physiological role not only of P2X1 but also of P2X1-containing hetero-oligomers and potentially other P2X homo-oligomers in native cells.
Of interest is the finding that the dominant negative P2X1 mutant was
present in the platelets of a patient presenting a severe bleeding
disorder. Indeed, since stimulation of platelets with ADP or
,
-methylene ATP results in a rapid Ca2+ influx
through platelet P2X1 channels (6), a role for this channel in normal
homeostasis can be hypothesized.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Dr J. Eggermont (Leuven) for providing the pCINeoIRES-GFP bicistronic vector.
| |
FOOTNOTES |
|---|
* This work was supported by the Interuniversitaire Attractipool program (IUAP 3P4/23) and Geconcerteerde Onderzoeksacties (GOA 99/07), FWO G.0237.95, FWO G.0214.99, FWO G.0136.00, by "Levenslijn" (7.0021.99), and Grant R7115 B0 from the "Alphonse and Jean Forton-Koning Boudewijn Stichting" (to B. N.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Holder of a postdoctoral research fellowship of the FWO.
§ Beneficiant of a Soros Foundation scholarship and a subsequent SANOFI research fellowship.
¶ Holder of a clinical fundamental research mandate of the FWO.
** Holder of the "Dr. J. Choay Chair in Haemostasis Research."

To whom correspondence should be addressed: Center for
Molecular and Vascular Biology, University of Leuven, Herestraat 49, B-3000 Leuven, Belgium. Tel.: 32-16-346145; Fax: 32-16-345990; E-mail:
marc.hoylaerts@med.kuleuven.ac.be.
Published, JBC Papers in Press, May 17, 2000, DOI 10.1074/jbc.C000305200
| |
ABBREVIATIONS |
|---|
The abbreviations used are: GFP, green fluorescent protein; F, farad(s).
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Burnstock, G. (1996) CIBA Found. Symp. 198, 1-34 |
| 2. | Ravelic, V., and Burnstock, G. (1998) Pharmacol. Rev. 50, 413-492 |
| 3. | MacKenzie, A. B., Surprenant, A., and North, R. A. (1999) Ann. N. Y. Acad. Sci. 868, 716-729 |
| 4. | Collo, G., North, R. A., Kawashima, E., Merlo-Pich, E., Neidhart, S., Surprenant, A., and Buell, G. (1996) J. Neurosci. 16, 2495-2507 |
| 5. | Clifford, E. E., Parker, K., Humphreys, B. D., Kertesy, S. B., and Dubyak, G. R. (1998) Blood 91, 3172-3181 |
| 6. | MacKenzie, A. B., Mahaut-Smith, M. P., and Sage, S. O. (1996) J. Biol. Chem. 271, 2879-2881 |
| 7. | Mulryan, K., Gitterman, D. P., Lewis, C. J., Vial, C., Leckie, B. J., Cobb, A. L., Brown, J. E., Conley, E. C., Buell, G., Pritchard, C. A., and Evans, R. J. (2000) Nature 403, 86-89 |
| 8. | Cattaneo, M., and Gachet, C. (1999) Arterioscler. Thromb. Vasc. Biol. 19, 2281-2285 |
| 9. | Torres, G. E., Egan, T. M., and Voigt, M. M. (1999) J. Biol. Chem. 274, 22359-22365 |
| 10. | Werner, P., Seward, E. P., Buell, G. N., and North, R. A. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 15485-15490 |
| 11. | Koshimizu, T., Koshimizu, M., and Stojilkovic, S. S. (1999) J. Biol. Chem. 274, 37651-37657 |
| 12. | Boué-Grabot, E., Archambault, V., and Séguéla, P. (2000) J. Biol. Chem. 275, 10190-10195 |
| 13. | Rassendren, F., Buell, G., Newbolt, A., North, R. A., and Surprenant, A. (1997) EMBO J. 16, 3446-3454 |
| 14. | Egan, T. M., Haines, W. R., and Voigt, M. M. (1998) J. Neurosci. 18, 2350-2359 |
| 15. | Trouet, D., Nilius, B., Voets, T., Droogmans, G., and Eggermont, J. (1997) Pfluegers Arch. 434, 632-638 |
| 16. | Evans, R. J., Lewis, C., Buell, S., Valera, S., North, R. A., and Surprenant, A. (1995) Mol. Pharmacol. 48, 178-183 |
| 17. | Evans, R. J., Lewis, C., Virinio, C., Lundstrom, K., Buell, G., Surprenant, A., and North, R. A. (1996) J. Physiol. (Lond.) 497.2, 413-422 |
| 18. | Torres, G. E., Egan, T. M., and Voigt, M. M. (1999) J. Biol. Chem. 274, 6653-6659 |
| 19. | Lê, K., Boué-Grabot, E., Archambault, V., and Séguéla, P. (1999) J. Biol. Chem. 274, 15415-15419 |
This article has been cited by other articles:
![]() |
C. Oury, M. J. E. Kuijpers, E. Toth-Zsamboki, A. Bonnefoy, S. Danloy, I. Vreys, M. A. H. Feijge, R. De Vos, J. Vermylen, J. W. M. Heemskerk, et al. Overexpression of the platelet P2X1 ion channel in transgenic mice generates a novel prothrombotic phenotype Blood, May 15, 2003; 101(10): 3969 - 3976. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Scheinman, H. S. Tenenhouse, D. Prie, G. Friedlander, and C. Silve Nephrolithiasis, Osteoporosis, and Mutations in the Type 2a Sodium-Phosphate Cotransporter N. Engl. J. Med., January 16, 2003; 348(3): 264 - 265. [Full Text] [PDF] |
||||
![]() |
R. A. North Molecular Physiology of P2X Receptors Physiol Rev, October 1, 2002; 82(4): 1013 - 1067. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Oury, E. Toth-Zsamboki, J. Vermylen, and M. F. Hoylaerts P2X1-mediated activation of extracellular signal-regulated kinase 2 contributes to platelet secretion and aggregation induced by collagen Blood, September 18, 2002; 100(7): 2499 - 2505. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Oury, E. Toth-Zsamboki, J. Vermylen, M. F. Hoylaerts ;, N. J. Greco, G. Tonon, W. Chen, X. Luo, R. Dalal, and G. A. Jamieson Does the P2X1del variant lacking 17 amino acids in its extracellular domain represent a relevant functional ion channel in platelets? Blood, March 15, 2002; 99(6): 2275 - 2277. [Full Text] [PDF] |
||||
![]() |
P. J. Jensik, D. Holbird, M. W. Collard, and T. C. Cox Cloning and characterization of a functional P2X receptor from larval bullfrog skin Am J Physiol Cell Physiol, September 1, 2001; 281(3): C954 - C962. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |